---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-056839"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:46:55.485667+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs appoints Dr. Clay Siegall and Dr. Kate Sasser to board of directors

## Summary
- Appointments effective March 1, 2024; board now includes two new independent directors.
- Dr. Siegall is CEO/Chairman of Immunome (IMNM) and former CEO/Chairman of Seagen (acquired by Pfizer).
- Dr. Sasser is Chief Scientific Officer of Tempus AI and previously led translational research at Genmab and J&J.
- Co. expects clinical updates for SL-172154 mid-2024 and plans late-stage/pivotal studies in multiple indications.

## SEC filing metadata
- accession: 0001193125-24-056839
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000119312524056839/0001193125-24-056839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000119312524056839/d806380d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-056839
- JSON: https://secwatch.observer/filing/0001193125-24-056839.json
- Plain text: https://secwatch.observer/filing/0001193125-24-056839.txt

## Key facts
- Executive change
  Dr. Clay Siegall was appointed as Class III director at Shattuck Labs, Inc..
  - Action: appointed
  - Role: Class III director
  source text: On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680367/000119312524056839/0001193125-24-056839-index.htm
- Executive change
  Dr. Kate Sasser was appointed as Class II director at Shattuck Labs, Inc..
  - Action: appointed
  - Role: Class II director
  source text: On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680367/000119312524056839/0001193125-24-056839-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.